Immunology and Allergy Clinics of North America 2001: Vol 21 Index

23 Pages·2001·5.5 MB·English

CUMULATIVE INDEX 2001
Volume 21
February HUMORAL IMMUNODEFICIENCIES, pages 1-190
May SKIN TESTING, pages 191-402
August THE DIFFICULT ASTHMATIC, pages 403-610
November ANAPHYLAXIS, pages 611-861
Note: Page numbers of article titles are in boldface type
Acetaminophen, for immune globulin with unidentified molecular defect,
therapy reactions, 177 53-54
Acetylcysteine, for status asthmaticus, X-linked, 23-43
520-521 animal models of, 34-35
Achondroplasia, with Swiss-type Btk protein defects in, 27-35
agammaglobulinemia, 122, 124 cancer in, 26
Acrodysplasia, in spondylo-mesomelic- clinical manifestations of, 24
acrodysplasia with joint dislocations diagnosis of, 35-37
and immunodeficiency, 123, 125 growth hormone deficiency with, 94
Adenosine deaminase deficiency, heterogeneity in, 27
immunodeficiency in, 92, 94, 121-122, historical background of, 23-24
124 immunopathology of, 27-29
Adherence, to asthma treatment, 415-416, infections in, 24-26
578, 589-604 molecular basis of, 28, 30
failure of, 405 mortality in, 27
consequences of, 592-593 treatment of, 37-39
factors in, 593-595 Age, skin test variations with, 282, 294
forms of, 592 Air poliution, asthma in, 421-423
goals of, 589-590 fatalities related to, 539-540
improvement of, 595-598 Airway, edema of, in anaphylaxis, 617, 627
practice guidelines for, 590-591 Albuterol
psychosocial factors in, 594-595, 598-601 for anaphylaxis, 626, 628, 791
Adhesion molecules, inhibitors of, for for asthma, 510, 516-519, 552
asthma, 565 Alcohol abuse, asthma with, 480-481
Alginic acid, for gastroesophageal reflux,
Adrenal gland
459
dysfunction of, asthma with, 481 ALK lancet, for skin testing, 266-268
hemorrhage of, anaphylaxis with, 818 Allergens
Agammaglobulinemia, 45-63 for skin testing, 251-261
animal models of, 54-60 food, 257-258
B lymphocyte development and, 45-50 fungal, 254-256
in B cell-linker protein defects, 53 geographical considerations in, 252-
in Iga and Igb mutations, 51-52 253
in mu-heavy chain mutations, 50-51 indoor, 255, 257
in surrogate light chain defects, 52-53 intradermal, 330-331
Swiss-type, achondroplasia with, 122, number required for, 251-252
124 pollen-derived, 254
842 CUMULATIVE INDEX 2001
Allergens (Continued) in radiocontrast media allergy, 699-706
potency of, determination of, 344 pathogenesis of, 796-798
prick-puncture, 333 pathophysiology of, 799
quality of, 284 prevention of, 807-808
selection of, 294 Anaphylaxis, 611-634
standardized, 258-259, 337-343 administration route and, 613
stinging insects, 257 adrenal hemorrhage with, 818
venom, 307-308 allergist’s responsibilities in, 827-839
hidden, anaphylaxis due to, 822 background for, 828
latex, 671-672 documentation, 828-830
Allergy emergency treatment, 832-834
aluminum salt, 728-729 information resources, 834-835
anaphylaxis in. See Anaphylaxis. patient and public education, 829-831,
anesthetic agent. See Anesthesia, anaphy- 834-836
laxis and anaphylactoid reactions re- preventive measures, 831-832
lated to. public health issues, 836-837
antibiotic, 679-697 approach to, in anesthesia, 807
in vaccines, hypersensitivity to, 726- biphasic, 619-620, 819
727 cardiac effects of, 616-617
perianesthesia, 802 causes of, 618-619, 828
aspirin. See Aspirin, anaphylactoid reac- challenge test in, 776
tions to. classification of, idiopathic, 790-791
casein, anaphylaxis in, 822 clinical features of, 611, 620
drugs for, evaluation of, skin testing in, exercise-induced, 769-770
348 idiopathic, 784
egg protein, in vaccines, 711, 717-723 in anesthesia, 798-799
fish, versus scombroidosis, 819-821 in food allergy, 655-658
food. See Food allergy; specific foods. in insect sting allergy, 638-639
gelatin in vaccines, 723-726 in unusual presentations, 815-816
insect sting. See Insect sting allergy. covert allergens in, 822-823
latex. See Latex allergy. definition of, 795-796
phenoxyethanol in vaccines, 732 diagnosis of
skin testing for. See Skin testing. idiopathic, 786, 788-790
tartrazine, 757 in anesthesia, 798
thimerosal, 727-728 in food allergy, 659-662
vaccine components. See Vaccines, hyper- in insect sting allergy, 640-641, 645-
sensitivity to. 646
Allerprick device, for skin testing, 267 in latex allergy, 671-673
Alternaria immunotherapy, reactions to, differential diagnosis of, 620-621
709 exercise-induced, 777
Alternative therapy, for asthma, 565-566, idiopathic, 786-788
580-583 in anesthesia, 798-799, 806-807
Aluminum, in vaccines, hypersensitivity in food allergy, 660
to, 728-729 epidemiology of, 612-613, 828
Aminophylline idiopathic, 783-784
for anaphylaxis, 626 in anesthesia, 798
for status asthmaticus, 517-518, 523 in food allergy, 653-654
Anaphylactoid reactions in latex allergy, 670-671
approach to, 807 in radiocontrast media allergy, 701-
definitions in, 795-796 702
diagnosis of, 798 exercise-induced, 657-658, 769-782, 787—
differential diagnosis of, 798-799, 806- 788
807 factitious, 621
epidemiology of, 798 idiopathic, 783-794
in anesthesia. See Anesthesia, anaphy- causes of, 619
laxis and anaphylactoid reactions re- classification of, 790-791
lated to. clinical features of, 784
in antibiotic allergy, 683-684, 802 corticosteroid-dependent, 790-791, 793
in nonsteroidal anti-inflammatory drug diagnosis of, 786, 788-790
allergy, 683-684 differential diagnosis of, 786-788
CUMULATIVE INDEX 2001 843
epidemiology of, 783-784 antihistamines in, 625
frequency of, 790 community involvement in, 835-836
generalized, 790 corticosteroids in, 625-626, 778
malignant, 790 epinephrine in. See Epinephrine.
pathogenesis of, 784-786 exercise-induced, 777-778
prevention of, 793 glucagon in, 626-627
questionable, 790-791 idiopathic, 627-628, 791-793
treatment of, 627-628, 791-793 in airway obstruction, 627
variant, 790-791 in food allergy, 662-664
in anesthesia. See Anesthesia, anaphy- in insect sting allergy, 640-643
laxis and anaphylactoid reactions re- in latex allergy, 673-675
lated to. in profound hypotension, 817
in Anisakis simplex exposure, 821-822 oxygen in, 626
in antibiotic allergy, 679-697, 802 prehospital, 832-834
in beta-blocker use, 619 volume replacement in, 626-627
in casein allergy, 822 unusual presentations of, 813-825
versus foreign-body aspiration, 818
in food alleigy. See Food allergy, anaphy-
versus myocardial infarction, 817-818
laxis in.
with hypotension only, 816-817
in immune globulin therapy, 177-178
Anergy, skin tests for, 249, 385, 394
in immunotherapy, 708-711
Anesthesia
in insect sting allergy, 635-651 anaphylaxis and anaphylactoid reactions
in latex allergy, 669-677, 772-773 related to, 795-811
in penicillin allergy, 310-311
antibiotics, 802
in scombroidosis, 819-821 approach to, 807
in vaccine hypersensitivity, 707-743 benzodiazepines, 804
information resources for, 629, 663, 834— classification of, 796-797
835 colloid plasma expanders, 804
natural history of, 776-777 definitions in, 795-796
pathogenesis of diagnosis of, 798
idiopathic, 784-786 differential diagnosis of, 798-799, 806-
in anesthesia, 796-798 807
in antibiotic therapy, 681-683 epidemiology of, 798
in food allergy, 654-655 hypnotic induction agents, 801
pathology of, 617-618 latex, 802-804
pathophysiology of, 611-612, 614-616, local, 805-806
799 muscle relaxants, 799-800
peripheral vascular resistance variations opioids, 801
in, 816-817 pathogenesis of, 796-798
persistent, 619-620 pathophysiology of, 799
predisposing factors for, 613-614 prevention of, 807-808
prevention of, 628-630 protamine, 804-805
exercise-induced, 778-780 in asthma, 476, 515-516
local, allergy to, skin testing for, 314-315
idiopathic, 793
Angioedema
in anesthesia, 807-808 hereditary, versus idiopathic anaphy-
in food allergy, 663-664
laxis, 788
in immunotherapy, 710-711
in anaphylaxis, 611, 620
in insect sting allergy, 643-647 idiopathic, 784, 790
in radiocontrast media allergy, 704-
with unusual presentation, 815
705 in food allergy, 655
protracted, 819 in insect sting allergy, 639
recurrent, 619-620, 819 in NSAID sensitivity, 759-764
in insect sting allergy, 641 Angiotensin-converting enzyme inhibitors,
risk factors for for hypertension, asthma and, 479-480
in antibiotic therapy, 680-681 Animal allergen exposure, asthma in, 418
in insect sting allergy, 641-643 Anisakis simplex allergy, anaphylaxis in,
in radiocontrast media allergy, 703- 821-822
704 Ant sting allergy. See Insect sting allergy.
shock organs in, 616-617 Antibiotics
treatment of, 621-628 for common variable immunodeficiency,
adrenergic agonists in, 626 5-6
844 CUMULATIVE INDEX 2001
Antibiotics (Continued) meningitis, 758
for status asthmaticus, 521 pneumonitis, 759
in vaccines, hypersensitivity to, 726-727 prevention of, 763-764
systemic reactions to, 679-697 respiratory disease, 749-755
desensitization for, penicillins, 687-689 urticaria, 756-757, 759-764
diagnosis of avoidance of, in asthma, 479
nonpenicillins, 690-693 for immune globulin therapy reactions,
penicillins, 684-687 177
historical background of, 679-680 Asthma
pathogenesis of aspirin-induced, 747-755
immunoglobulin E-mediated, 681- difficult-to-manage
683 anatomic considerations in, 450
non-immunoglobulin E-mediated, anesthesia in, 476, 515-516
683-684 approach to, 409-410
perianesthesia, 802 arterial blood gas analysis in, 508
risk factors for, 680-681 cardiac effects of, 477
substitution in, penicillins, 690 cardiovascular disease with, 476-479
treatment of, nonpenicillins, 692-693 chest radiography in, 509
Antibody(ies) chronic obstructive pulmonary disease
for asthma treatment with, 473-476
chemokine, 564-565 clinical features of
immunoglobulin E, 561-562, 583 occupational, 492-494
interleukin-5, 562-563 steroid-resistant, 569-572
in asthma pathogenesis, 497 concomitant medical problems with,
Anticholinergic agents, for asthma, 473-488, 576-577
478-479 diagnosis of, 506-510
Antidepressants incorrect, 404-405
asthma and, 480 occupational, 494-497
skin testing results and, 284 rhinosinusitis and, 433-434
Antigen presenting cells steroid-resistant, 575-579
CD40 expression on, 67-68 differential diagnosis of, 403-412, 475-
in common variable immunodeficiency 476
pathogenesis, 15-16 embryologic considerations in, 450
Antigen washout, in delayed endocrine problems with, 481-482
hypersensitivity skin testing, 391 environmental risk factors in, 405-406,
Antihistamines 416-423, 579
for anaphylaxis, 625 exacerbating factor persistence in,
in food allergy, 663 405-406
for insect sting allergy, 640 fatality-prone, 503-504, 535-549
for NSAIDs sensitivity, 754 gastroesophageal reflux and. See Gas-
skin testing results and, 283 troesophageal reflux.
Apid sting allergy. See Insect sting allergy. gastrointestinal disorders with, 483-
Apnea, in gastroesophageal reflux, 442 484
Arachidonic acid metabolites, in genetic factors in, 491
anaphylaxis, 615 hospitalization criteria in, 507
Arthritis, in immunodeficiency hypertension with, 479-480
CD154 deficiency, 70 in pregnancy, 463, 481-482, 522-523
common variable, 8 liver disorders with, 484-485
X-linked agammaglobulinemia, 25 menstrual cycle and, 481-482
Arthropod sting allergy. See Insect sting mortality in, 503-504
allergy. natural history of, occupational, 498—
Arthus reaction, 194, 384 499
Aspiration neurogenic inflammation in, 452
foreign-body, versus anaphylaxis, 818 neurologic disorders with, 485-486
in gastroesophageal disease, asthma obesity with, 482-483
and, 456-457 occupational, 489-501
Aspirin pathology and pathogenesis of, 504—
anaphylactoid reactions to, 745-768
angioedema, 759-764 steroid-resistant, 572-575
cross-reactions and, 746-749, 754-758 treatment based on, 559-560
CUMULATIVE INDEX 2001 845
pathophysiology of, occupational, 497 Ataxia-telangiectasia, immunodeficiency
patient-physician relationship in, 597-— in, 99
Atenolol, asthma benefits from, 478
patient education for, 596 Atmospheric pollution, asthma fatalities
physical findings in, 508 related to, 539-540
physiologic considerations in, 505-506 Atopic dermatitis, in food allergy, 655-656
poor adherence in, 405 Atopy
prevalence of, 503-504 anaphylaxis and, 614, 773
psychiatric drug therapy and, 480 antibiotic allergy and, 680
psychologic factors in, 589-604 asthma in, 490
pulmonary function in, 495-496, 508, NSAID sensitivity and, 760-761
570-571 skin tests for, 203-204
reversibility of, 404-405 Atropine, for intubation, in status
rhinosinusitis in, 407-408, 427-437, asthmaticus, 513
577 Auranofin, for asthma, 566
risk factors for, 474-475, 490-491 Autoimmune disease, in
sensitization in, 492-494 immunodeficiency
socioeconomic risk factors in, 413-416
CD154 deficiency, 75
spirometric patterns in, 570-571
sputum analysis in, 508-509 common variable, 10
with spondylometaphyseal dysplasia,
status asthmaticus, 503-533
123, 125-126
steroid-resistant, 408-409, 569-587
Autonomic dysfunction
substance abuse with, 480-481, 490-
gastroesophageal reflux in, 455
491
treatment of, 510-522 in exercise-induced anaphylaxis, 774-775
adequacy of, 577-578 Avoidance
adherence to. See Adherence, to in anaphylaxis, 830-831
asthma treatment. exercise-induced, 778-780
alternative, 565-566, 580-583 idiopathic, 628-629
in food allergy, 663
anti-immunoglobulin E, 561-562,
in latex allergy, 673-675
583
anti-interleukin, 562-564 in asthma
antiadhesion molecule, 565 occupational, 499
antichemokine, 564-565 refractory, 523-524
anticholinergics in, 478-479
beta-adrenergic agonists in, 510,
538-539, 552, 555
B cell-linker protein defects,
compliance with. See Adherence, t= ) agammaglobulinemia in,
asthma treatment. 1S)o >)
B-cell Oct-binding protein-1,
corticosteroids in. See Corticoste-
agammaglobulinemia in, 55, 58
roid(s), for asthma.
drug interactions in, 578-579 B lymphocytes
gastrointestinal effects of, 483-484 absence of. See Agammaglobulinemia.
guidelines for, 590-591 deficiency of. See Hypogammaglobuli-
nemia.
inappropriate, 414-415
leukotriene-modifying agents in, development of, 30-32, 45-48
in common variable immunodeficiency
519, 556, 582-583
occupational, 499 pathogenesis, 14-15
pharmacologic, 551-568 in signaling, 48-50
phosphodiesterase inhibitors in, subsets of, in CD154 deficiency, 74
563-564 Bacterial allergy, skin testing for. See also
protease inhibitors in, 564 Tuberculin test.
rhinosinusitis and, 433-434 history of, 223-227, 242-248
steroid-resistant, 579-583 Barbiturates, allergy to, 801
theophylline in, 556 Barium studies, in gastroesophageal reflux,
unproven, 566 444
versus idiopathic anaphylaxis, 788 Basic helix-loop-helix-leucine zipper
exercise-induced, versus exercise-in- (BHLH-Zip), defects of,
duced anaphylaxis, 777 agammaglobulinemia in, 55, 58-59
radiocontrast media reactions and, 703- BCR complex, in B lymphocyte function,
704 47-48
846 CUMULATIVE INDEX 2001
Beclomethasone, for asthma, 553-554 in common variable immunodeficiency,
Bee sting allergy. See Insect sting allergy. 3-6
Benzodiazepines occupational, 492-493
allergy to, 804 Bronchodilators, for status asthmaticus,
for status asthmaticus, 515 516-517, 521-522
Beta-adrenergic agonists Bronchopulmonary dysplasia,
asthma fatalities related to, 538-539 corticosteroids in,
for anaphylaxis, 626 hypogammaglobulinemia in, 144
for asthma, 510, 555 Bronchospasm, aspirin-induced, 747-755
Beta-blockers Bruton’s tyrosine kinase gene. See BTK
anaphylaxis due to, 619 gene and product.
contraindicated in asthma, 477-480 BTK gene and product
Bethanecol, for gastroesophageal reflux, assays for, 36
446 characteristics of, 28, 30-32
Bifurcated needle, for skin testing, defects of, in X-linked agammaglobuli-
266-268, 274-275 nemia, 27-35
Biliary cirrhosis, asthma with, 484-485 Budesonide, for asthma, 553, 580
Biopsy, of skin test lesions, 348 Burns, hypogammaglobulinemia in, 154
Blood gases, arterial, in status asthmaticus,
Byssinosis, 494
508
Bloom’s syndrome, immunodeficiency in,
100-101
Bone dysplasias, immunodeficiencies with, Cancer
113-127 hypogammaglobulinemia in, 152-153
adenosine deaminase deficiency, 92, 94, in immunodeficiency
121-122, 124 ataxia-telangiectasia, 99
animal models of, 113-115 CD154 deficiency, 70, 72
cartilage hair hypoplasia, 119-120 common variable, 11, 14
cell-mediated, 119-121 X-linked agammaglobulinemia, 26
combined, 122-126 in Nijmegen breakage syndrome, 100
developmental relationships in, 113-115 Candidiasis, skin testing for, 391-392
DiGeorge syndrome, 103-104, 119-120 Carbamazepine, hypogammaglobulinemia
pathophysiology of, 113-115
due to, 147
Roifman syndrome, 116-119
Carbapenem allergy, skin testing for, 313
Schimke immunoosseous dysplasia, 120-
Carcinoid syndrome, versus idiopathic
121
short-limb, 92, 94, 115-117 anaphylaxis, 788
with ectodermal dysplasia, 122, 124— Cardiovascular disorders
125 asthma with, 476-479
in anaphylaxis, idiopathic, 784
with short stature and femoral bow-
ing, 123, 125 in radiocontrast media allergy, 700
spondylo-mesomelic-acrodysplasia with versus exercise-induced anaphylaxis, 777
joint dislocations, 123, 125 Carmine allergy, anaphylaxis in, 823
spondylometaphyseal dysplasia and au- Cartilage hair hypoplasia,
immunodeficiency in, 119-121
toimmunity, 123, 125-126
Casein allergy, 822
Swiss-type agammaglobulinemia and
Cat allergen exposure, asthma in, 418
achondroplasia, 122, 124
thymic dysplasia with dyschondroplasia, CD40 molecule
120 cells expressing, 66, 68
Bone marrow transplantation, in CD154 defective signaling of, in autosomal re-
deficiency, 79 cessive hyperimmunoglobulin M
Booster effect, in delayed hypersensitivity syndrome, 81-82
skin testing, 391 ligand for. See CD154 molecule.
Bowing, femoral, in short stature /limb physiology of, 65-68
dysplasia with immunodeficiency, 123, CD154 molecule, 65-89
125 assay for, 78
Bradykinin, in anaphylaxis, 615-616 CD40 interactions with, 65-68
Bronchial challenge tests, versus skin cells expressing, 66, 68
testing, 359-360 deficiency of (X-linked hyperimmunoglo-
Bronchitis bulin M syndrome), 68-79
chronic, asthma with, 473-476 case series of, 69-70, 82
CUMULATIVE INDEX 2001 847
clinical features of, 70-72 Chronobiologic variation, in skin testing,
diagnosis of, 69, 77-78 282, 295
discovery of, 68 Cimetidine
female carriers of, 76 for anaphylaxis, 625
genetics of, 76-77 for gastroesophageal reflux, 446
immunologic features of, 72-76 Clarithromycin, for infections, in status
treatment of, 78-7' asthmaticus, 521
versus autosomal recessive hyperim- Clinical Laboratory Improvement
munoglobulin M syndrome, 79-82 Amendments of 1988, skin testing
Celecoxib, anaphylactoid reactions to. See performance standards of, 321-322
Nonsteroidal anti-inflammatory drugs, Cocaine abuse, asthma with, 480-481
anaphylactoid reactions to. Coccidioidomycosis, skin testing for, 391
Cephalosporins Cochineal extract allergy, anaphylaxis in,
administration of, in penicillin-allergic 823
persons, 690 Cockroach allergen exposure, asthma in,
allergy to, skin testing for, 313 416-417
Challenge tests Collapse reaction, in vaccination, 732-733
bronchial, versus skin testing, 359-360 Colloid plasma expanders, allergy to, 804
in aspirin allergy, 749-750, 756, 761-763 Common variable immunodeficiency, 1-22
in asthma, 496 autoimmune disease in, 10
in exercise-induced anaphylaxis, 773- classification of, 2
774, 776 clinical features of
in food allergy, 661-662 gastrointestinal, 6-7
versus skin testing, 363-364 in enteroviral infections, 9-10
with exercise-induced anaphylaxis, in Mycoplasma infections, 8-9
773-774 respiratory, 3-6
in insect sting allergy, 642 definition of, 1-3
in latex allergy, 673 differential diagnosis of, 1-3
Chemical exposures, asthma in, 420-421, genetics of, 16-18
493 granulomatous inflammation in, 10-13
Chemokines, antibodies to, for asthma, immunoglobulin A deficiency and,
564-565 16-18
Chest radiography, in status asthmaticus, immunoglobulin replacement in, 14
509 immunopathogenesis of, 14-16
Chlamydia pneumoniae infections, asthma malignancy development in, 11, 14
and, 521,577 versus transient hypogammaglobuli-
Chlorpheniramine, for anaphylaxis, nemia of infancy, 136
idiopathic, 791 Complement, in anaphylaxis, 616, 774
Chlortetracycline, in vaccines, Compliance. See Adherence.
hypersensitivity to, 726 Contact allergy, skin testing for, history of,
Cholera vaccine, components of, 713 228-231
Cholinergic urticaria, versus exercise- Contact dermatitis, in immunotherapy, 709
induced anaphylaxis, 777 Contrast media. See Radiocontrast media.
Chromosomal abnormalities, Coronary arteries
immunodeficiency in, 97-105 anaphylaxis effects on, 616-617
ataxia-telangiectasia, 99 disease of, asthma with, 476-479
Bloom’s syndrome, 100-101 vasospasm of, in anaphylaxis, 817-818
chromosome 18 partial deletions, 104 Corticosteroid(s)
DiGeorge sequence or syndrome, 103- action of, at molecular level, 5
104, 119-120 for anaphylaxis, 625-626, 778
ICF syndrome, 101-102 for asthma, 552-555
Nijmegen breakage syndrome, 99-100 adverse reactions to, 553-554
Seckel syndrome, 100 inhaled, 553-554
trisomy 21, 102 mechanism of action of, 552
Turner’s syndrome, 104 oral, 554-555
Wolf-Hirschhorn syndrome, 104-105 refractory, 510-512, 523
Chromosome 18 partial deletions, steroid-resistant, 580
immunodeficiency in, 104 for insect sting allergy, 640
Chronic obstructive pulmonary disease, hypogammaglobulinemia due to, 142-
asthma with, 473-476 144
848 CUMULATIVE INDEX 2001
Corticosteroid(s) (Continued) mechanisms of, 383-384
skin testing results and, 284 multitest-cell-mediated immunity, 393
Corticosteroid-resistant asthma, 408-409, Delayed reactions, in skin testing, 204-206
569-587 DermaPik, for skin testing, 267-270, 288
assessment of, 575-579 Dermatitis
clinical features of, 569-572 atopic, in food allergy, 655-656
definition of, 569-570 contact
differential diagnosis of, 575-576 in immunotherapy, 709
in pediatric patients, 570 skin testing for, history of, 228-231
pathogenesis of, 572-575 Dermatologic conditions,
treatment of, 579-583 immunodeficiency with, 94-96
Cough, in asthma, 505 Desensitization
Cricothyrotomy, for airway obstruction, in for antibiotic allergy, 687-689
anaphylaxis, 627 for NSAIDs sensitivity, 750-751, 754
Crohn’s disease, hypogammaglobulinemia Dextran, allergy to, 804
in, 152 Diabetes mellitus, asthma with, 481
Cushing’s syndrome, asthma with, 481 Dialysis, hypogammaglobulinemia in, 150
Cutaneous basophil hypersensitivity, Diarrhea
versus delayed hypersensitivity, 384 in CD154 deficiency, 70
CXCR4, defects of, agammaglobulinemia in common variable immunodeficiency,
in, 55, 57 6-7
Cyclooxygenase inhibitors, anaphylactoid Diet, for gastroesophageal reflux, 445-446,
reactions to. See Nonsteroidal anti- 459
inflammatory drugs, anaphylactoid DiGeorge sequence or syndrome,
reactions to. immunodeficiency in, 103-104,
Cyclosporine, for asthma, 566, 581 119-120
Cytokines Dilution, in skin testing. See Serial
dysregulation of dilution-titration skin test.
in common variable immunodeficie- Diphenhydramine
ncy, 16 for anaphylaxis, 625
in transient hypogammaglobulinemia idiopathic, 791
of infancy, 132 for radiocontrast media reaction preven-
in asthma, 497, 505, 559-560 tion, 702
in reactions to gelatin-containing vac- in immune globulin therapy reactions,
cines, 724-725 177
Cytomegalovirus infections, Diphtheria vaccines
hypogammaglobulinemia in, 156 bacterial antigens in, hypersensitivity to,
729
components of, 712
DNA-binding defects, in steroid-resistant
Darier’s sign, in mastocytosis, 788 asthma, 574-575
Death. See Fatalities. DNA methyltransferase 3B, defects of,
Delayed hypersensitivity skin testing, immunodeficiency in, 101
383-397 Documentation
antigen washout in, 391 of anaphylaxis, 828-830
booster effect in, 390 of skin testing results, 277-279
for candidiasis, 391-392 intradermal, 331
for coccidioidomycosis, 391 prick-puncture, 335-336
for histoplasmosis, 391 variability related to, 288-289
for immunocompetence, 394 Dopamine, for anaphylaxis, 627
for mumps, 392 Doppler studies, of skin test lesions, 347
for previous exposure, 393-394 Down syndrome (trisomy 21),
for tetanus toxoid, 392 immunodeficiency in, 102
for Trichophyton, 393 Doxycycline, for Mycoplasma infections, in
for tuberculosis, 385-386, 389-391, 393- common variable immunodeficiency,
394 8-9
future of, 394-395 Drug(s)
indications for, 385 abuse of, asthma with, 480-481, 490-491
interpretation of, 386, 388-389 allergy to
Mantoux method, 385-386 diagnosis of, 310
CUMULATIVE INDEX 2001 849
in multiple drug allergy syndrome, in NSAIDs sensitivity, 753
681 Ephedrine, for radiocontrast media
skin testing for, 298, 309-316 reaction prevention, 702
versus idiopathic anaphylaxis, 788 Epicutaneous skin testing, 263-272
for allergies, evaluation of, skin testing devices for, 273-276
in, 348 comparison of, 266-270
hypogammaglobulinemia due to, 142- history of, 263-264
147 modern, 264-266
skin testing results and, 283-284, 295 variable results and, 287-288
Duotip Test, 268-270, 288 documentation of, 278
Dust allergy history of, 207-208, 263-264
asthma in, 494 interpretation of, 293
skin testing for, allergen selection for,
technique for, 273-276
255, 257 versus intracutaneous/intradermal skin
Dust mite allergen exposure, asthma in, testing, 276-277, 285-287
416-418 Epilepsy, asthma with, 485
Dwarfism, short-limb, immunodeficiency
Epinephrine
with, 92, 94
adverse effects of, 623-624
and ectodermal dysplasia, 122, 124-125
for anaphylaxis, 623-625
with short stature and femoral bowing,
exercise-induced, 778-780
123, 125
idiopathic, 627-628, 791
Dysgammaglobulinemia, in Nijmegen
in food allergy, 662-663
breakage syndrome, 100
patient education on, 829
prehospital, 832-834
self-administration of, 627, 629, 832-
E 25 (anti-immunoglobulin antibodies), for 834
asthma, 561-562, 583 for status asthmaticus, 510
E2A gene, mutations of, Epstein-Barr virus infections,
agammaglobulinemia in, 54-56 hypogammaglobulinemia in, 155-156
Early B-cell factor, defects of, Erythema, in insect sting, 638
agammaglobulinemia in, 55-56 Esophagitis, in gastroesophageal reflux,
Ectodermal dysplasia, short-limb dwarfism
and immunodeficiency with, 122, Esophagus
124-125 manometry of, in gastroesophageal re-
Edema, airway, in anaphylaxis, 618 flux, 445
Education, on anaphylaxis, patient and neuroanatomy of, 451-452
public, 829-831, 834-836 reflux into. See Gastroesophageal reflux.
Egg protein, in vaccines, hypersensitivity Evaporation tests, of skin test lesions, 347
to, 711, 717-723 Exercise, anaphylaxis in, 769-782
Elderly persons challenge test in, 776
asthma in, fatality risk and, 541 clinical features of, 769-770
gastroesophageal reflux in, 456, 463 differential diagnosis of, 777
Electrophoresis, in skin testing, 208-209 food-dependent, 657-658, 770-776
Emphysema, asthma with, 473-476 natural history of, 776-777
Endoscopy, of small intestine, in prevention of, 778-780
gastroesophageal reflux, 445 treatment of, 777-778
Endotracheal intubation versus idiopathic anaphylaxis, 787-788
for anaphylaxis, 627
for status asthmaticus, 512-513
Enterocolitis, food-induced, 658
Enterovirus infections, in Failure to thrive, in gastroesophageal
immunodeficiency reflux, 442
common variable, 9-10 Familial intestinal polyatresia,
X-linked agammaglobulinemia, 25-26 immunodeficiency with, 97
Environmental risk factors, for asthma, Family dysfunction, in asthma treatment
416-423, 579 adherence, 594-595
indoor, 416-421 Famotidine, for gastroesophageal reflux,
outdoor, 421-423 446
Eosinophils Fatalities
in asthma, 509, 559 in anaphylaxis, 612-613, 623
850 CUMULATIVE INDEX 2001
Fatalities (Continued) Food and Drug Administration
in food allergy, 656-658 intracutaneous/intradermal skin test pro-
in insect sting allergy, 639 cedure of, 330-331
in latex allergy, 671 skin testing performance standards of,
in penicillin allergy, 680 321-325
in radiocontrast media allergy, 701 Foreign-body aspiration, versus
in vaccine hypersensitivity, 708, 710- anaphylaxis, 818
711 Formacid sting allergy. See Insect sting
in asthma, 535-549 allergy.
after hospital admission, 540-541 Fundoplication, for gastroesophageal
epidemiology of, 535-536 reflux, 464
Fungal allergy, skin testing for, allergen
in nonadherence, 592
patient characteristics in, 537 selection for, 254-256
risk factors for, 536-541
age, 541
atmospheric pollution, 539-540
Gastritis, in common variable
drug-related, 538-539
immunodeficiency, 7
heterogeneity of, 541-542 Gastroesophageal reflux, 449-471
hypersensitivity, 537-538, 540
anatomic considerations in, 450
socioeconomic, 538 asthma and, 406-407, 491
viral infections, 540 historical perspective of, 449-450
seasonal patterns in, 539 in pediatric patients, 446-447
sudden, 535, 537 microaspiration in, 456-457
Femur, bowing of, in short stature/limb prevalence of, 452, 454-455
dysplasia with immunodeficiency, 123, vagal reflexes in, 457
125 versus steroid-resistant asthma, 576—
Fenoterol, for asthma, fatalities related to, 577
535, 538 diagnosis of, 459
Fentanyl allergy, 801 embryologic considerations in, 450
Fire ant sting allergy. See Insect sting esophageal innervation and, 452-453
allergy. evaluation of, 457-459
Fish, ingestion of, anaphylaxis related to, factors promoting, 455-456
819-822 historical perspective of, 449-450
Flea bites, allergy to, 648 in elderly persons, 456, 463
Fluid therapy in pediatric patients, 439-448
for anaphylaxis, 626-627 asthma and, 446-447
for status asthmaticus, 512 classification of, 440
Flunisolide, for asthma, 553-554 clinical features of, 440-443
diagnosis of, 443-445
Fluticasone, for asthma, 553-554, 580
Fly bites, allergy to, 647-648 functional, 440-441
pathologic, 441-443
Folic acid malabsorption,
pathophysiology of, 439-440
immunodeficiency with, 97
physiologic, 440
Food allergy
anaphylaxis in, 618, 629, 653-667 secondary, 443
treatment of, 445-446
clinical features of, 655-658
in pregnancy, 463
diagnosis of, 659-662
pathophysiology of, 451-452
differential diagnosis of, 660
treatment of, 459-465
epidemiology of, 653-654
Gastrointestinal disorders
exercise-induced, 657-658, 770-776 asthma with, 483-484
from hidden allergens, 822-823 hypogammaglobulinemia in, 151-152
pathogenesis of, 654-655
immunodeficiency with, 6-7, 97
prevention of, 663-664, 836-837 Gelatin, in vaccines, hypersensitivity to,
treatment of, 662-664 723-726
versus idiopathic anaphylaxis, 787 Gender, skin test variations with, 283,
enterocolitis in, 658 294-295
natural history of, 664 Gene therapy, for X-linked
skin testing for agammaglobulinemia, 38-39
allergen selection for, 257-258 General anesthesia, in anesthesia. See
interpretation of, 297 Anesthesia, anaphylaxis and
versus challenge tests, 363-364 anaphylactoid reactions related to.